Physician

Liza R Varghese, MD

According to 2025 Medicare claims, Liza Varghese, MD (NPI: 1952306193) practices rheumatology in the Cincinnati, OH-KY-IN market, with the plurality of this provider's patient population coming from Boone, KY. This provider's primary affiliated billing organization is TRISTATE ARTHRITIS & RHEUMATOLOGY PSC (NPI: 1851449425; TIN: 611104130) and primary practice location at 41017-2418. Varghese is affiliated with the Healthcare Solutions Network (ACO ID: A3283) and Caravan Health ACO 50 LLC (ACO ID: A5160), participating under the MSSP model.

Varghese's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 292 traditional Medicare patients, billed 165,489 HCPCS/CPT codes, and received $1,560,120 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,684 prescription claims across 291 beneficiaries totaling $955,228 in drug costs, led by Humira(Cf) Pen (Adalimumab). 2021 DME data shows 12 claims. Open Payments data shows 121 records totaling $4,564. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $787,258 to $1,560,120. Similarly, Part D prescription costs have risen steadily, from $491,074 to $955,228. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $0 to $1,238.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	375	35,604	$787,258
2016	383	36,834	$905,804
2017	361	40,232	$1,001,674
2018	398	47,218	$1,372,814
2019	429	66,158	$1,390,071
2020	382	66,455	$1,111,183
2021	373	94,926	$1,336,001
2022	331	119,206	$1,278,004
2023	300	129,204	$1,193,281
2024	292	165,489	$1,560,120

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	383	2,041	$491,074
2016	334	1,949	$582,634
2017	297	1,776	$548,192
2018	336	1,958	$785,186
2019	360	2,009	$762,456
2020	330	1,841	$841,764
2021	325	1,717	$634,995
2022	286	1,469	$820,583
2023	282	1,580	$955,800
2024	291	1,684	$955,228

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$745
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	12	$1,317
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	256	704	$87
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	99	590	$48
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	213	478	$12
96372	Injection of drug or substance under skin or into muscle	122	301	$10
J1010	Injection, methylprednisolone acetate, 1 mg	121	29,820	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	46	1,344	$322,079
Orencia Clickject	Abatacept	40	1,120	$227,905
Enbrel Sureclick	Etanercept	21	588	$154,431
Rinvoq	Upadacitinib	13	390	$81,313
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	191	13,810	$7,280

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	121	$4,564	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Liza R. Varghese, MD?

Tedicare shows public-source Medicare data for Liza R. Varghese, MD (NPI 1952306193), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Liza R. Varghese, MD have ACO affiliation data?

Liza R. Varghese, MD is shown with ACO affiliation data for Healthcare Solutions Network (MSSP, ACO ID A3283) and Caravan Health ACO 50 LLC (MSSP, ACO ID A5160).

What billing organization is linked to Liza R. Varghese, MD?

Liza R. Varghese, MD is linked to TRISTATE ARTHRITIS & RHEUMATOLOGY PSC (billing NPI 1851449425) in the available physician profile data.

Does Liza R. Varghese, MD have Open Payments data?

Liza R. Varghese, MD has 121 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.